News
Video
Author(s):
Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
Revisit Every OncLive On Air Episode From May 2024
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC
FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma